Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M

Bibliographic Details
Published in:	Global Medical Genetics
Main Author:	Xiaoying Zhang
Format:	Article
Language:	English
Published:	KeAi Communications Co., Ltd. 2021-06-01
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1731067

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
by: Asim Joshi, et al.
Published: (2022-08-01)

Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell  Lung Cancer Patients with Acquired EGFR T790M Mutation
by: Yanfei GU, et al.
Published: (2022-12-01)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
by: Yosuke Miyashita, et al.
Published: (2021-02-01)

Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report
by: Bradley Steiner, et al.
Published: (2025-06-01)

Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations
by: Yingxue Li, et al.
Published: (2024-08-01)

Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis
by: Guojin Zhou, et al.
Published: (2024-01-01)

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
by: Leiming Xia, et al.
Published: (2021-07-01)

Co-existence of EGFR T790M-acquired lung adenocarcinoma and transformation into small-cell carcinoma in different organs after osimertinib treatment. A case report
by: Masahide Takeda, et al.
Published: (2025-09-01)

The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis
by: Liuxian Guo, et al.
Published: (2024-04-01)

Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report
by: Sunny Y. Lai, MD, et al.
Published: (2024-04-01)

Advanced lung adenocarcinoma harboring uncommon EGFR 19 Del and T790M/trans-C797S mutations after resistance: a case report and literature review
by: Yuting Xiao, et al.
Published: (2025-04-01)

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer
by: Hye Sook Kim, et al.
Published: (2023-06-01)

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review
by: Chihiro Maeda, et al.
Published: (2023-10-01)

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
by: Lavinia Tan, et al.
Published: (2024-02-01)

Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR‐ANXA2, EGFR‐RAD51, ATR and BRCA2 mutations: A case report
by: Rui Zhong, et al.
Published: (2020-02-01)

Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M
by: Nur Zam Zam, et al.
Published: (2023-10-01)

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
by: Yingqi Xu, et al.
Published: (2025-12-01)

Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China
by: Xiangcheng Li, et al.
Published: (2025-10-01)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
by: Hanping Wang, et al.
Published: (2020-03-01)

Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with <i>EGFR</i> G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review
by: Wenting Lu, et al.
Published: (2025-03-01)

Editorial - T790M mutation and clinical outcomes with genuine osimertinib
by: Purvish M Parikh
Published: (2019-01-01)

Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review
by: Xue YANG, et al.
Published: (2023-02-01)

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial–mesenchymal transition
by: Kejun Liu, et al.
Published: (2021-05-01)

Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation
by: Chi-Lu Chiang, et al.
Published: (2020-09-01)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
by: Ou Yamaguchi, et al.
Published: (2023-11-01)

A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib
by: Umberto Malapelle, et al.
Published: (2022-09-01)

Stevens–Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring EGFR mutations 19 del/T790M/C797S in trans and cis: a case report
by: Yang Chen, et al.
Published: (2023-11-01)

A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma
by: Zhiyi Han, et al.
Published: (2024-08-01)

Efficacy of osimertinib in advanced T790M-positive NSCLC after progression to prior EGFR-TKI: real world data from a Brazilian cohort
by: Luiz Henrique Araujo, et al.
Published: (2020-01-01)

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report
by: Daphnée Demers, et al.
Published: (2025-05-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
by: Kaibo Ding, et al.
Published: (2024-08-01)

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis
by: Xinyue Wang, et al.
Published: (2025-04-01)

EGFR T790M-Positive Lung Adenocarcinoma Metastases to the Pituitary Gland Causing Adrenal Insufficiency: A Case Report
by: Michael L. Adashek, et al.
Published: (2018-01-01)

Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis
by: Yin Shi, et al.
Published: (2022-10-01)

Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations
by: Hongyue Qin, et al.
Published: (2022-09-01)

A patient with a lung adenosquamous carcinoma harboring a de novo T790M mutation and huge nonbacterial vegetative growths successfully treated with osimertinib: A case report
by: So‐yun Kim, et al.
Published: (2023-06-01)

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
by: Yubo Wang, et al.
Published: (2022-04-01)

Osimertinib as Salvage Therapy in Advanced Non‐Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report
by: Yongtong Tang, et al.
Published: (2025-02-01)

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation
by: Shanliang Hu, et al.
Published: (2022-08-01)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M

Similar Items

Similar Items